Genetic Technologies Limited announce the development of the Company?s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will be a world first; including over 200 high penetrant genes to unlock the hereditary disease risk to its current multi-test associated with the most common cancers, cardiovascular disease, and type 2 diabetes. This ground-breaking innovation enables doctors to identify nearly 100% of people at risk of disease going beyond family history, which is only responsible for 5-15%.

Importantly the test includes sporadic non-hereditary disease which is linked to the remaining 85% of people. This population wide test will identify patients at risk of serious disease in nearly 70% of annual mortalities and morbidities and remains a simple non-invasive sample. GeneType is committed to clinically validated innovation advancing its current portfolio offering unparalleled insight into an individual's risk of serious diseases.

This cutting-edge test represents a significant leap forward in personalized preventative healthcare, providing physicians and their patients with an unprecedented tool to tailor interventions and treatment plans. Key features of GeneType's Comprehensive Risk Assessment Test: Includes more than 200 High Penetrant Genes: GeneType's test goes beyond conventional assessments, incorporating an extensive panel of hereditary genes, ensuring a comprehensive evaluation of the individual's genetic predisposition to serious diseases whether user have a family history or not. Numerous publications have highlighted the importance of using multigene panels compared with just genetic tests for one or two genes.

In one study of 10,000 patients, approximately 50% the pathogenic genes identified in patients with breast or ovarian cancer were in genes other than BRCA1/21. In the event no genetic mutations are identified, in the case of breast cancer this will be approximately 90% of patients2, the geneType Comprehensive Risk Assessment Test includes an automatic reflex that captures the majority of patients at risk of these serious diseases. Saliva Test: geneType?s patented non-invasive saliva test remains at the core of GeneType's approach, ensuring accessibility and ease for patients while maintaining the highest standards of accuracy.

Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.